Neuralstem (CUR) Earns Media Impact Rating of 0.18

Press coverage about Neuralstem (NASDAQ:CUR) has been trending somewhat positive on Sunday, according to Accern. The research group identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Neuralstem earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave headlines about the company an impact score of 46.1478180327446 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Here are some of the headlines that may have effected Accern Sentiment Analysis’s rankings:

Neuralstem (NASDAQ:CUR) traded down 1.46% during midday trading on Friday, hitting $1.35. The stock had a trading volume of 166,153 shares. The stock has a 50-day moving average price of $1.23 and a 200 day moving average price of $3.63. Neuralstem has a one year low of $0.22 and a one year high of $6.60. The firm’s market cap is $16.36 million.

Neuralstem (NASDAQ:CUR) last announced its quarterly earnings results on Tuesday, August 8th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($9.49) by $9.10. Neuralstem had a negative return on equity of 321.78% and a negative net margin of 198,573.91%. On average, analysts predict that Neuralstem will post ($2.26) earnings per share for the current year.

Separately, ValuEngine cut Neuralstem from a “hold” rating to a “sell” rating in a research note on Tuesday, July 25th.

COPYRIGHT VIOLATION NOTICE: “Neuralstem (CUR) Earns Media Impact Rating of 0.18” was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at

About Neuralstem

Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.

Insider Buying and Selling by Quarter for Neuralstem (NASDAQ:CUR)

Insider Buying and Selling by Quarter for Neuralstem (NASDAQ:CUR)

Receive News & Ratings for Neuralstem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem Inc. and related companies with's FREE daily email newsletter.

Leave a Reply